How the United States Government Became the Food Industry’s Partner in Harm

A documented record of revolving doors, presidential complicity, congressional capture, and the systematic betrayal of public health — from Reagan to Trump

A companion paper to POISONED BY DESIGN

THE NEWS THAT PROMPTED THIS PAPER

On February 18, 2026 — yesterday, as this paper is being written — President Donald Trump signed an Executive Order invoking the Defense Production Act to guarantee the domestic supply of glyphosate-based herbicides, formally designating them a national security priority. The White House fact sheet described glyphosate as enabling ‘healthy, affordable food options’ for American families. The order grants producers partial liability immunity under the Defense Production Act for actions taken in compliance with federal directives — potentially complicating future cancer litigation against manufacturers.

FEBRUARY 18, 2026: On the same day this executive order was signed, Bayer — the company that acquired Monsanto and its Roundup product — had already paid nearly $11 billion to settle more than 120,000 lawsuits from people who claimed glyphosate caused their cancer. The product the president just designated a national security asset has been classified by the World Health Organization’s cancer agency as a probable human carcinogen.

RFK Jr., now Secretary of Health and Human Services, had previously won a nearly $290 million judgment against Monsanto on behalf of a groundskeeper whose cancer was linked to Roundup. He told a Senate confirmation hearing that he could not take any step that would put a farmer out of business and that ‘there’s a million farmers who rely on glyphosate.’ His most prominent public crusade became the policy position he abandoned most completely upon taking office.

This is not a story about one president, one party, or one executive order. It is a story about a system. A system in which the regulatory agencies responsible for protecting Americans from industrial food chemicals have been, for decades, staffed at their senior levels by the people who built those chemicals, sold those chemicals, and returned to selling them after brief tours in government. A system in which the science guiding food policy is primarily funded by the industries whose profits that science affects. A system in which the political machinery of both parties has been shaped, year after year, by money from the same corporations whose products are documented in the companion paper to this one to be making Americans chronically ill.

This Is Not a Partisan Story: The corruption documented in this paper is not partisan. Democrats and Republicans have served this system with equal dedication, across every administration from Nixon to the present. The corporations do not have party registration. Neither does their money. And neither does the harm they cause.

PART ZERO: WHERE IT ACTUALLY STARTED — NIXON, BUTZ, AND THE ARCHITECTURE OF THE PROBLEM

The revolving door between Monsanto and the FDA is the most documented chapter of corporate capture of American food policy. But it is not the first chapter. To understand how the system was built — and why it has been so difficult to dismantle — you have to go back further than Reagan, further than the Monsanto Protection Act, further than Michael Taylor’s first tour through the FDA. You have to go back to 1971. To Richard Nixon. To a USDA Secretary named Earl Butz. And to a political decision that was made not for public health, not for farmers, and not for the American people — but to win an election.

Nixon’s Problem: Food Prices and a Coming Election

In 1971, Richard Nixon faced a political crisis. Food prices were rising sharply. Inflation was visible in every grocery store in America, and Nixon — facing reelection in 1972 — needed food prices to come down. He appointed Earl Butz as Secretary of Agriculture in November 1971. Butz arrived at the USDA with an explicit mandate: make food cheap. And with the open backing of agribusiness corporations who had long despised the New Deal agricultural policies that stood between them and unlimited commodity profits.

Butz’s confirmation was approved by the Senate 51 to 44 — an extraordinarily narrow margin for a cabinet appointment — because Democratic senators recognized that his documented ties to agribusiness corporations represented a conflict of interest. He had served on the boards of Ralston Purina and other major agricultural corporations before his appointment and continued to represent their worldview throughout his tenure. The senators who voted against him were right. They were outvoted.

The Destruction of Supply Management: Dismantling the Farmer’s Protections

The New Deal agricultural policy Butz inherited had been built during the Great Depression for a specific reason: the dust bowl and the Depression had demonstrated that unchecked overproduction destroyed farmers, devastated land, and produced surpluses that helped no one. The Ever-Normal Granary program, designed by Henry Wallace, paid farmers to leave some land fallow when prices fell, preventing ruinous overproduction while maintaining price stability. It was, in other words, a market management system designed to protect both farmers and consumers from the volatility of industrial commodity agriculture.

Butz despised it. He called it socialism. He abolished it. His replacement policy was simple and brutal: maximize production, find foreign buyers for the surplus, and let the market determine what happened to farmers who could not compete at the scale the new policy required. His slogan — ‘get big or get out’ — was not a metaphor. It was a policy directive. Farmers who could not afford to expand their acreage, buy the new machinery, and adopt the industrial inputs the new model required went bankrupt. Between 2017 and 2022 alone — decades after Butz left office, but following the trajectory he established — over 141,000 farms disappeared, a nearly 7% decline in five years according to the USDA’s own census.

A Policy Designed to Harm Farmers: Butz’s ‘get big or get out’ policy was explicitly designed to benefit agribusiness corporations — who needed cheap, unlimited commodity inputs — at the direct expense of small family farmers, who were eliminated by the millions over the following decades. This was not a market outcome. It was a designed policy outcome, executed by a USDA Secretary who had sat on the boards of the corporations that benefited.

The Soviet Grain Deal: Engineering the Corn Glut

In 1972, Butz engineered a massive grain sale to the Soviet Union — which had suffered crop failures and desperately needed grain. The Soviets bought approximately 28% of the entire U.S. wheat crop in a single year. Grain prices tripled. Farmers, encouraged by Butz’s ‘fence row to fence row’ exhortations, took on enormous debt to plant as much corn and soy as possible to capitalize on high prices. Butz had created the demand. Now he needed a use for the inevitable surplus when demand normalized.

The surplus came. Corn prices collapsed. And the question of what to do with mountains of subsidized corn that nobody needed became the defining food policy question of the mid-1970s. The answer that Butz and the agribusiness industry settled on would reshape the American diet for the next 50 years and is one of the most consequential food policy decisions in American history — though it is almost never discussed as such.

The HFCS Decision: How Nixon’s Politics Created the Obesity Epidemic

High fructose corn syrup (HFCS) was not invented in America. It was developed by Japanese food scientists in the 1960s — specifically, a chemist named Yoshiyuki Takasaki, working in Chiba City, Japan, patented the commercial production process in 1971. The enzyme that makes it possible — glucose isomerase — converts ordinary corn starch into a liquid sweetener with a higher fructose content than regular corn syrup. The Japanese had the technology. It needed a market.

The market was created by American government policy. The Nixon administration’s domestic sugar protections — import tariffs and quotas dating to the New Deal that kept American sugar prices artificially high — made HFCS an attractive substitute as soon as the technology became commercially viable. The Butz corn surplus policy made the raw material — commodity corn — artificially cheap. The combination of protected domestic sugar prices and subsidized corn prices created a structural price advantage for HFCS that had nothing to do with its quality or safety. It was cheaper because government policy made it cheaper.

Archer Daniels Midland — a politically connected agribusiness giant whose CEO, Dwayne Andreas, had been personally involved in advising Nixon on the Soviet grain deal — used its political muscle to expand HFCS production and create markets for it. By the mid-1970s, HFCS was commercially available. By the early 1980s it had entered the mainstream food supply. In 1984, Coca-Cola switched its flagship American beverage formula to HFCS. By the mid-1980s, HFCS had largely replaced sugar in processed foods across America. It was soon added to pizza, coleslaw, meat, bread, condiments, yogurt, and virtually every packaged product in American supermarkets.

Global Development and Environment Institute / Tufts University: The annual per-capita consumption of caloric sweeteners has increased by 40 pounds in the last 40 years. High fructose corn syrup accounts for 81% of the 83 additional daily calories the average American consumes from sweeteners. This is not a consumer preference story. It is a government policy story — beginning with Nixon’s electoral calculus in 1971.

Why HFCS Matters: The Metabolic Difference

HFCS is not merely a different form of sugar. It is metabolically distinct from sucrose (table sugar) in ways that are directly relevant to the obesity epidemic documented in the companion paper. Sucrose is a disaccharide that must be cleaved into glucose and fructose by intestinal enzymes before absorption. HFCS delivers fructose in a free, immediately absorbable form. Fructose is metabolized almost exclusively in the liver, where it bypasses the regulatory mechanisms that govern glucose metabolism. At high doses, fructose metabolism in the liver promotes de novo lipogenesis — the conversion of fructose directly to fat — and impairs insulin signaling. It does not trigger the same satiety signals as glucose. It does not significantly stimulate leptin production. It does not suppress ghrelin, the hunger hormone.

In practical terms: a food system saturated with free fructose from HFCS delivers continuous liver fat production signals, undermines the body’s capacity to know when it has eaten enough, and drives insulin resistance — the metabolic root of type 2 diabetes. The peer-reviewed literature on fructose metabolism and obesity is extensive and largely consistent on these mechanisms. What it rarely notes is that the fructose load in the American diet exists because a president needed food prices to come down in 1971 and his Agriculture Secretary needed to find a use for surplus corn in 1973.

CDC Historical Obesity Data / PMC5464749: The obesity epidemic tracks the HFCS adoption curve with uncomfortable precision. Adult obesity was 14.5% in 1971, when Nixon appointed Butz. By 2000, after two decades of HFCS saturation of the food supply, it had more than doubled to 30.9%. By 2023 it was 40.3%. This is not correlation as accident. This is the biological consequence of a policy decision made for electoral reasons, without any consideration of its health effects.

The Butz Connections: Corporate Boards and Captured Policy

Earl Butz was not a disinterested public servant who happened to make policies that benefited agribusiness. He was an agribusiness insider who happened to be given control of the USDA. At the time of his appointment, he served on the boards of Ralston Purina — then one of the largest food conglomerates in America — and several other agricultural corporations. He represented their worldview, their priorities, and their hostility to any policy that limited their access to cheap commodity inputs. His Senate confirmation was contested specifically because of these ties. He was confirmed anyway. Nixon needed his vision for the USDA, and Butz delivered it.

The pattern Butz established — USDA leadership drawn from agribusiness board membership, serving agribusiness interests from inside the regulatory agency, returning to agribusiness after government service — is the same pattern that has characterized USDA leadership in every administration since. Butz did not invent the revolving door. But he built the room it opens into: an industrial food system so thoroughly designed around the interests of large commodity corporations that every subsequent USDA Secretary, regardless of party, has operated within the framework he constructed.

The Legacy: Everything That Followed

The significance of the Nixon-Butz decisions for everything documented in this paper cannot be overstated. The policy of maximizing corn and soy production created the raw material base for industrial grain-fed livestock — the animals that accumulate the POPs, glyphosate residues, PFAS, and synthetic hormones documented in Poisoned by Design. The elimination of supply management created the economic pressure on farmers to adopt every yield-maximizing technology — GMO seeds, glyphosate, synthetic fertilizers — regardless of safety concerns. The HFCS decision flooded the American food supply with a metabolically disruptive sweetener at the precise moment the low-fat dietary guidelines were telling Americans to replace fat with carbohydrates.

The three decisions together — maximize corn production, use the surplus to replace sugar with HFCS, eliminate the policy protections that allowed small farms to survive — created the industrial food system that all subsequent corporate capture has operated within and profited from. Reagan did not build this system. He expanded it. Clinton did not build this system. He staffed it. Obama did not build this system. He protected it. Trump did not build this system. He is currently invoking the Defense Production Act to guarantee its continuation.

Richard Nixon built it. He built it to win an election. And 50 years and an obesity epidemic later, 300 million Americans are living inside what he built.

The Origin of the Indifference: Nixon’s motivation was electoral. Butz’s motivation was ideological and corporate. ADM’s motivation was profit. Nobody in that chain of decision-making was thinking about what free fructose would do to the livers of the children who would be born into the food system they were constructing. That is the indictment. Not malice — indifference. Indifference to consequences that were not their problem, that would not arrive until after the election, after their tenure, after their deaths.

PART ONE: THE REVOLVING DOOR — NAMES, DATES, POSITIONS

Michael Taylor: The Man Who Moved Most Freely

No single figure better illustrates the revolving door between the food industry and the regulatory agencies meant to govern it than Michael Taylor. His career is not a metaphor. It is a documented record spanning five decades and multiple administrations of both parties. It deserves to be understood in full.

1. 1970s: Taylor works as a staff attorney and executive assistant to the FDA Commissioner — under Nixon and Reagan administrations.
2. 1981–1991: Taylor joins the Washington law firm King & Spalding, where he represents Monsanto and authors articles arguing against the Delaney Clause — a 1958 federal law prohibiting introduction of known carcinogens into processed food.
3. 1991: Taylor returns to the FDA as Deputy Commissioner for Policy — a newly created position — under George H.W. Bush. He now oversees FDA food policy.
4. 1992: Taylor signs the FDA guidance statement that milk from cows treated with Monsanto’s bovine growth hormone (BGH) does not have to be labeled as such. Monsanto manufactures BGH. Taylor’s prior law firm represented Monsanto. The agency he now leads does not require disclosure.
5. 1994: Bill Clinton appoints Taylor to the USDA as Food Safety and Inspection Administrator. During this period Taylor attempts to persuade the FDA and FTC to make it illegal for dairies to label their milk as BGH-free — directly protecting Monsanto’s market position.
6. 1996–2009: Taylor returns to Monsanto as Vice President for Public Policy.
7. 2009: Barack Obama appoints Taylor as Senior Advisor to the FDA Commissioner.
8. 2010: Obama appoints Taylor to the newly created position of FDA Deputy Commissioner for Foods — effectively the second-highest food safety position in the federal government.

Taylor’s career is a complete circuit: FDA → Monsanto law firm → FDA → USDA → Monsanto → FDA. He moved between the regulator and the regulated so many times and so seamlessly that the distinction between the two became meaningless. At every stage of his government career, he made decisions that benefited his former and future employer. At no stage was he required to recuse himself from matters affecting Monsanto. At no stage did any administration — Republican or Democrat — refuse to appoint him.

The Taylor Record: While Taylor was at the USDA in the mid-1990s, he attempted to make it illegal for dairy producers to tell consumers their milk was free of Monsanto’s growth hormone. He was not acting outside his authority. He was using government power to protect a private corporation’s market position. That is not regulatory capture as an abstraction. That is regulatory capture with a name, a date, and a target.

Margaret Miller: Approving Her Own Work

Margaret Miller worked as a chemical laboratory supervisor at Monsanto, where she helped prepare the safety report that Monsanto submitted to the FDA for approval of its bovine growth hormone. Shortly before the report was to be submitted, Miller left Monsanto and was appointed Deputy Director of the FDA’s Office of New Animal Drugs. Her first assignment in that role was to review and rule on the Monsanto report she had helped prepare. She approved it. No conflict of interest review was required. No recusal was required. Monsanto, in effect, reviewed its own product.

The Full Roster: Administration by Administration

Reagan Administration

David Bockorny — Reagan’s legislative affairs specialist: became a Monsanto tax consultant after leaving government.

William D. Ruckelshaus — First EPA Administrator (1970): later served on Monsanto’s Board of Directors. Ruckelshaus also served as Acting FBI Director. The first administrator of the agency designed to protect Americans from industrial chemicals served the company producing them.

George H.W. Bush Administration

Michael Taylor — FDA Deputy Commissioner for Policy (1991): previously Monsanto’s outside counsel at King & Spalding. Created a new FDA position to accommodate his return to government.

Clarence Thomas — U.S. Supreme Court Justice (appointed 1991): worked as an attorney in Monsanto’s pesticide and agriculture division from 1977–1979. In 2001, Thomas wrote the Supreme Court’s majority opinion in a GMO patent case that significantly benefitted Monsanto. He did not recuse himself.

Clinton Administration

Michael Taylor — USDA Food Safety Administrator: simultaneously worked on behalf of Monsanto’s market interests, attempting to prohibit BGH-free dairy labeling.

Michael Kantor — U.S. Trade Representative (1993–1996); Secretary of Commerce (1996–1997): was a Monsanto lawyer and board member who served as campaign chair for the Clinton-Gore campaign in 1992. He used his trade representative role to promote GMO crop adoption internationally.

William Cable — Carter/Clinton Deputy Assistant for Legislative Affairs: became a Monsanto lobbyist.

Seth Waxman — Clinton-era Department of Justice: listed among Monsanto’s government relations connections.

George W. Bush Administration

Ann Veneman — Secretary of Agriculture: had previously served as a director of Calgene, a Monsanto subsidiary, before her appointment.

Donald Rumsfeld — Secretary of Defense: was CEO of Searle Pharmaceuticals, which was acquired by Monsanto. Rumsfeld had direct corporate lineage to Monsanto and served in Bush’s cabinet overseeing defense policy while Monsanto lobbied for global GMO adoption through State Department channels.

Tommy Thompson — Secretary of Health and Human Services: received documented campaign contributions from Monsanto.

John Ashcroft — Secretary of Justice: received documented campaign contributions from Monsanto during his Senate career in Missouri — Monsanto’s home state.

Islam Siddiqui — appointed Chief Agricultural Negotiator, Office of the U.S. Trade Representative: former Vice President of CropLife America, a Monsanto affiliate trade organization. He used the trade representative role to push GMO crop acceptance internationally.

Linda Fisher — EPA Deputy Administrator: had been Monsanto’s Vice President of Government and Public Affairs before her EPA appointment, and returned to industry after leaving government.

Obama Administration

Michael Taylor — FDA Deputy Commissioner for Foods (2010): completing his third tour through the FDA after two stints at Monsanto.

Roger Beachy — First Director of USDA National Institute of Food and Agriculture (NIFA): his research at Washington University in St. Louis was conducted in direct collaboration with Monsanto Company, leading to development of the world’s first genetically modified food crop.

Tom Vilsack — Secretary of Agriculture: in 2001 had been honored by the Biotechnology Industry Organization as ‘Governor of the Year’ for his support of biotech industry growth. Vilsack later returned to serve as Agriculture Secretary under Biden as well.

Jess Rowland — EPA Deputy Director of Pesticide Division: court documents allege Rowland told a Monsanto executive in a 2015 phone call that he ‘should get a medal’ if he could kill another government agency’s investigation into glyphosate. Rowland left the EPA under unexplained circumstances shortly after a glyphosate report he authored was leaked and then immediately withdrawn.

Obama Signs the Monsanto Protection Act, 2013: President Obama signed the ‘Monsanto Protection Act’ — formally the Farmer Assurance Provision (Section 735 of H.R. 933) — on March 26, 2013, despite a petition signed by over 250,000 Americans urging him not to. The provision prohibited federal courts from halting the planting or sale of GMO crops even if a court found them dangerous to human health. It stripped the judiciary of its oversight role over GMO safety at the direct request of the biotech industry.

Trump Administration (First Term, 2017–2021)

Aurelia Skipwith — Director of U.S. Fish and Wildlife Service: former Monsanto employee, nominated by Trump to oversee the Endangered Species Act, which governs how pesticides affecting wildlife are regulated.

Sonny Perdue — Secretary of Agriculture: oversaw continuation of glyphosate approvals and rollback of GMO labeling regulations.

Internal Monsanto records revealed in litigation in 2021 showed that a corporate intelligence firm hired to assess regulatory attitudes reported to Monsanto: ‘A domestic policy adviser at the White House said: We have Monsanto’s back on pesticides regulation. We are prepared to go toe-to-toe on any disputes they may have with, for example, the EU. Monsanto need not fear any additional regulation from this administration.’ The report was dated July 2018.

Trump White House to Monsanto, 2018: A White House domestic policy adviser told a private intelligence firm hired by Monsanto that the administration had ‘Monsanto’s back on pesticides regulation.’ This is not an allegation or an inference. It is a documented quote from internal Monsanto records filed in federal litigation.

During Trump’s first term, the administration reversed an Obama-era ban on chlorpyrifos — a pesticide linked to brain damage in children — at the direct request of Dow Chemical, which manufactures it. The administration also pulled proposed new regulations for GMO crops that had been in development under Obama, shelving regulatory modernization at the request of Monsanto, Dow, and other biotech lobbyists.

Biden Administration

Tom Vilsack — Secretary of Agriculture (again): returned for a second term as Agriculture Secretary, maintaining the same industry-favorable orientation he had demonstrated under Obama.

Despite President Biden’s first-day executive order pledging to limit exposure to dangerous chemicals and pesticides, his administration subsequently defended multiple Trump-era pesticide decisions in court — including the five-year registration of dicamba despite EPA Inspector General findings of improper political influence in its original approval. The administration used Trump-era methodology in its assessment of malathion, a toxic pesticide that government scientists had previously determined would jeopardize more than 1,200 endangered species.

The Bipartisan Pattern: The Biden administration, which came to office promising to restore science-based regulatory policy, defended Trump-era pesticide approvals in federal court. The promises change with each administration. The pesticide approvals persist across all of them.

Trump Administration (Second Term, 2025–present)

On February 18, 2026 — the day before this paper was completed — President Trump invoked the Defense Production Act to guarantee the supply of glyphosate-based herbicides, formally designating a probable human carcinogen as a national defense priority. The order grants partial liability immunity to producers acting under federal directive, potentially shielding Bayer-Monsanto from further litigation. RFK Jr., whose entire public profile was built in significant part on suing Monsanto for glyphosate cancer harm, is now the Secretary of Health and Human Services under the president who just gave Monsanto legal cover. Kennedy has softened his public position on glyphosate since taking office.

The Legal Shield, February 2026: The executive order of February 18, 2026 does not merely protect glyphosate’s commercial future. By invoking the Defense Production Act, it creates a federal compliance shield that producers may use to argue that their actions in producing and distributing glyphosate were mandated by the federal government — potentially complicating or limiting the cancer liability lawsuits that have already cost Bayer $11 billion.

PART TWO: THE MONEY — HOW CONGRESS IS PURCHASED

Pharmaceutical and Agribusiness: The Two Dominant Spending Forces

The revolving door explains how individual regulators serve industry interests. Campaign finance explains why legislators allow it. The money flows are not speculative. They are documented in federal disclosure filings, analyzed by OpenSecrets, and published in peer-reviewed research. The numbers tell a straightforward story: the industries responsible for the contamination of the American food supply are also the industries that most aggressively purchase access to the legislators and regulators who could hold them accountable.

The pharmaceutical and health products industry has been the single largest lobbying spender in the United States for more than 25 consecutive years. From 1999 to 2024, the industry spent over $6.1 billion on federal lobbying — an average of approximately $240 million per year, every year, without interruption. In 2024 alone, the industry spent $384.5 million on federal lobbying. A peer-reviewed study published in JAMA Internal Medicine found that from 1999 to 2018, the industry spent $4.7 billion on federal lobbying and $414 million on direct contributions to presidential and congressional candidates — with the contributions specifically targeted at members of Congress sitting on committees with jurisdiction over health legislation.

JAMA Internal Medicine, PMC7054854: Of the 40 members of Congress who received the most pharmaceutical industry contributions between 1999 and 2018, 39 belonged to committees with jurisdiction over health-related legislation, and 24 of them held senior positions on those committees. The industry did not distribute money broadly. It invested precisely where health policy is made.

The pharmaceutical industry currently has more than three registered lobbyists for every single member of Congress — 1,834 registered pharmaceutical lobbyists for 535 congressional seats. More than half of those lobbyists are revolving-door hires who previously held government positions. This is not a lobbying operation. It is an occupying force inside the legislative process.

The Farm Bill: Agriculture’s Parallel Machinery

The pharmaceutical industry’s capture of health policy has a direct parallel in agricultural policy. A 2024 report by the Union of Concerned Scientists found that agribusiness, food, and pharmaceutical manufacturing interests spent more than $523 million lobbying Congress specifically on the Farm Bill between 2019 and 2023. That is more than four times the combined lobbying spending of nonprofits, labor unions, state and local governments, and tribal nations — the entities that represent the public interest in farm and food policy. Every lobbying dollar from public interest organizations was matched by more than four dollars from the industries the Farm Bill is supposed to regulate.

The Farm Bill governs agricultural subsidies, food safety standards, pesticide regulations, GMO crop policy, school lunch nutrition standards, and food assistance programs. It is, effectively, the document that determines what Americans eat and under what chemical conditions their food is grown. And the entities with the most money, the most access, and the most influence over its content are the same agribusiness and food corporations whose products are documented in the companion paper to this one to be making Americans sick.

Union of Concerned Scientists, 2024: Campaign contributions to the chairs and ranking members of the House and Senate Agriculture Committees — the legislators who write the Farm Bill — came predominantly from agribusiness, food manufacturers, and pharmaceutical companies with direct financial interests in the bill’s outcome. The people writing the rules for what Americans eat are funded by the industries selling it.

PART THREE: THE CAPTURED AGENCIES

The FDA: Regulating Its Former Employer

The Food and Drug Administration is tasked with ensuring the safety of the American food and drug supply. It has been led, at senior levels, by a rotating cast of industry executives so consistently that independent scientists have a name for the pattern: regulatory capture. The Taylor case is the most extensively documented, but it is not unusual. It is the norm.

The FDA’s 1992 position that genetically engineered foods are ‘substantially equivalent’ to natural foods — the legal doctrine that allowed GMO crops to enter the American food supply without safety testing — was developed under Michael Taylor’s supervision while he was the FDA’s Deputy Commissioner for Policy. The doctrine was not derived from scientific consensus. Internal FDA documents obtained through Freedom of Information Act requests showed that the agency’s own scientists had expressed concerns about GMO food safety that were overridden by Taylor’s office. The Substantial Equivalence doctrine has been the legal foundation for the absence of GMO food safety testing in the United States ever since.

Dr. Michael A. Friedman served as the FDA’s Deputy Commissioner before joining Monsanto as a Senior Vice President. William D. Ruckelshaus served as EPA Administrator before joining Monsanto’s Board. Linda Fisher served as EPA Deputy Administrator after serving as Monsanto’s VP of Government and Public Affairs. Gwendolyn King served as Commissioner of the Social Security Administration before joining Monsanto’s Board of Directors.

The Revolving Door Pattern: The pattern of movement between Monsanto and federal regulatory agencies spans five decades, both major political parties, and virtually every senior food and environmental regulatory position in the federal government. This is not coincidence. It is structural.

The EPA: The Agency That Chose Industry Over Its Own Scientists

The most explosive documented case of EPA capture involves its assessment of glyphosate. In 2015, the World Health Organization’s International Agency for Research on Cancer classified glyphosate as a probable human carcinogen based on independent scientific review. The EPA, reviewing the same chemical, concluded it was not likely to be carcinogenic. A 2021 paper in Toxicology Reports documented that the EPA relied primarily on industry-funded studies while the IARC relied on independent research. The agencies examined the same chemical and produced opposite findings because they examined different evidence from different funders.

The EPA’s internal process was not merely scientifically compromised. It was allegedly subject to direct personal intervention. Court documents from glyphosate litigation revealed that Jess Rowland, then the EPA’s Deputy Division Director for Pesticide Programs, allegedly told a Monsanto executive in 2015 that he ‘should get a medal’ for killing a separate government agency’s investigation into glyphosate carcinogenicity — referring to a Health and Human Services inquiry that would have provided independent scientific assessment. Rowland left the EPA in 2016 under unexplained circumstances, approximately two weeks after a draft EPA glyphosate report he had authored was leaked and then immediately withdrawn from public access.

Rowland / Monsanto, 2015–2016: An EPA official allegedly told a Monsanto executive he should receive a medal for suppressing a government cancer investigation into glyphosate. He left the EPA shortly thereafter and entered private industry consulting. No investigation into his conduct was completed. No accountability followed.

Trump’s EPA overturned an Obama-era ban on chlorpyrifos — a pesticide linked to brain damage in children, including at the doses commonly found in food — at the request of Dow Chemical, despite the agency’s own scientists recommending the ban be maintained. The EPA Inspector General later found that senior Trump administration officials had exerted improper political influence in the approval of dicamba, a related herbicide. In both cases, political appointees overrode career scientists to produce regulatory outcomes favorable to industry.

The USDA: Promoting the Industry It Regulates

The USDA’s structural conflict of interest — the agency tasked with promoting American agriculture is also the agency tasked with telling Americans what to eat — was documented in Part Two of the companion paper. Here it is worth emphasizing the specific ways this conflict has operated in practice.

In 1991, the USDA completed a new food guidance graphic — the predecessor to the food pyramid — and then refused to release it. Internal documents later obtained through FOIA requests showed the decision was made after pressure from meat and dairy industry representatives who objected to the graphic’s suggestion that Americans eat less meat. A government agency suppressed its own public health guidance because the truth was bad for an industry it was also charged with promoting. The guidance that was eventually released had been revised to remove the specific language industry found threatening.

Tom Vilsack, who served as Agriculture Secretary under both Obama and Biden, had been honored by the Biotechnology Industry Organization as Governor of the Year in 2001 for his support of the industry. He oversaw agricultural policy through eight years of Obama administration GMO expansion and returned to the same role under Biden. During his tenure the USDA’s organic and regenerative agriculture programs were consistently underfunded relative to conventional and biotech agriculture programs — reflecting the same priority structure that has governed the department for decades.

PART FOUR: THE SUPREME COURT AND THE SEED MONOPOLY

The final institutional protection for the industrial food system is the one least discussed in public debate: the federal judiciary. Specifically, the U.S. Supreme Court has played a direct role in consolidating corporate control over the seed supply — the foundational input for all food production.

In 2001, the Supreme Court ruled in J.E.M. Ag Supply v. Pioneer Hi-Bred International that plant utility patents were valid, allowing corporations to patent living seed varieties and prevent farmers from saving and replanting them. Justice Clarence Thomas wrote the majority opinion. Clarence Thomas worked as an attorney in Monsanto’s pesticide and agriculture division from 1977 to 1979. He did not recuse himself from a case that directly shaped the intellectual property framework under which Monsanto’s patented GMO seed business operates. The ruling has been described by agricultural economists as a foundational moment in corporate consolidation of the American seed supply.

Thomas / Monsanto / J.E.M. Ag Supply, 2001: A Supreme Court Justice wrote the majority opinion in a case establishing the legal framework for GMO seed patents — without disclosing or recusing himself from his prior employment by the company whose business model most benefited from the ruling. This is the judicial branch of the same revolving door that operates in the executive and regulatory branches.

The consolidation enabled by this and subsequent patent decisions has been profound. In 1996, before the widespread adoption of GMO crops, hundreds of seed companies competed in the American market. By 2018, three companies — Bayer-Monsanto, DowDupont (now Corteva), and ChemChina-Syngenta — controlled 60% of the global seed market. The seed that grows American food is now predominantly owned by the same chemical corporations that manufacture the pesticides those seeds are engineered to tolerate. The farmer who buys Monsanto’s Roundup Ready corn must also buy Monsanto’s Roundup. The corporate integration is complete, and it was enabled by a Supreme Court ruling written by a former Monsanto attorney.

PART FIVE: THE SYSTEM — HOW IT ALL WORKS TOGETHER

This Is Not Corruption. It Is Architecture.

It is tempting to describe what this paper documents as corruption — and corruption is present. The Rowland-Monsanto phone call, the suppression of the 1991 USDA food guide, the Monsanto Protection Act slipped into a spending bill without congressional debate — these are corrupt acts. But focusing on individual acts of corruption misses the larger reality: the system documented here does not require individual corruption to function. It is architecturally designed to produce outcomes that serve industry.

When the USDA has a statutory mandate to promote agriculture and also writes dietary guidelines, no individual corruption is required to produce guidance that protects agricultural industry revenue. The conflict is structural. When 74% of food industry lobbyists are former government employees, no bribery is required to ensure that regulatory proposals are softened before they become rules. The access is systemic. When industry funds the majority of nutrition research, no falsification of data is required to produce a literature that trends toward industry-favorable conclusions. The incentive structures do the work.

This is what political scientists mean by regulatory capture: a condition in which regulatory agencies advance the commercial and political interests of the industries they are supposed to regulate, rather than the public interest they were created to protect. Capture does not require scandal. It requires only that the people making regulatory decisions have closer professional, financial, and social ties to the industry than to the public — which, as the preceding sections document, describes virtually every senior food regulatory appointment across the past five decades.

Regulatory Capture: Regulatory capture does not require corruption. It requires only that the people making decisions have spent their careers in — and expect to return to — the industry they regulate. That condition has been continuously true of American food and agricultural regulation since at least the 1970s. The system is working as designed. The design is the problem.

The Closed Loop: How the System Sustains Itself

The system sustains itself through five interlocking mechanisms, each reinforcing the others:

• The revolving door ensures that regulatory agencies are staffed by people whose professional identities, relationships, and future employment prospects are tied to the industries they regulate. Genuine adversarial regulation becomes personally costly and professionally risky.
• Campaign finance ensures that legislators whose committees have oversight over food and drug policy are financially dependent on the industries those committees oversee. Vigorous oversight becomes electorally dangerous.
• Industry-funded research ensures that the scientific literature available to regulators trends toward industry-favorable conclusions. Regulation based on ‘the science’ is regulation based on purchased science.
• Lobbying at four to one over public interest organizations on the Farm Bill ensures that when legislation is written, the technical details — the thresholds, the exemptions, the enforcement mechanisms — reflect industry preferences rather than public health imperatives.
• Legal mechanisms — patent protections, liability shields, the Substantial Equivalence doctrine — provide corporate protections that are difficult to reverse once established, preserving the status quo even when political will for change exists.

The result is a system in which the regulatory decisions affecting 330 million Americans’ food supply are made by people who came from industry, are funded by industry, rely on industry-funded science, and will return to industry when their government service ends. The public, whose health is affected by every decision this system makes, has four times less lobbying representation than the corporations selling them food. Its children eat in schools whose lunch programs are designed by a department that is simultaneously mandated to promote agricultural sales. Its cancer risk from pesticide exposure is assessed by an agency whose senior officials have documented communication with the pesticide manufacturers about how to manage that assessment.

The Structural Conclusion: This is not a failure of the system. The system is functioning as designed — by the people who designed it. The question is not how to fix a broken regulatory apparatus. The question is whether the American people will demand a regulatory apparatus that is not architected around industry service.

PART SIX: WHAT ACCOUNTABILITY ACTUALLY REQUIRES

The companion paper, Poisoned by Design, documents what industrial food chemicals are doing to the bodies of Americans and their children. This paper documents the governmental architecture that has allowed it to continue. Together, they point toward what genuine accountability would require — not individual prosecutions, which are difficult and rare, but structural changes that remove the incentive architecture sustaining the system.

Structural Reforms That Would Change the System

1. Mandatory, enforced cooling-off periods: A minimum five-year prohibition on movement between senior regulatory positions and any industry the agency regulates — in either direction. Currently, cooling-off periods for senior officials are often one year, rarely enforced, and riddled with exceptions. The Taylor model — moving between Monsanto and the FDA three times across five decades — should be structurally impossible, not merely frowned upon.
2. Public funding for nutrition and food safety research: The scientific literature that guides regulatory decisions should not be primarily funded by the industries whose products are being assessed. A dedicated federal fund for independent food safety research, insulated from industry contribution, would change the evidence base that regulators rely on.
3. Separation of USDA promotional and regulatory mandates: The agency charged with promoting American agricultural sales and the agency charged with protecting Americans from the risks of that agriculture should not be the same agency. The structural conflict of interest is not manageable within the current architecture. It requires separation.
4. Mandatory conflict-of-interest disclosure and recusal on dietary guideline committees: Industry-funded researchers and industry-affiliated scientists should be excluded from serving on or advising the committees that set the national dietary guidelines. Disclosure is insufficient if disclosed conflicts do not trigger recusal.
5. Transparency in lobbying and campaign contributions by health-affecting industries: The same transparency required of pharmaceutical companies disclosing clinical trial funding should apply to food and agricultural industry funding of nutrition research, regulatory science, and public health communications.
6. Congressional jurisdiction reform: The committees with legislative jurisdiction over food safety should not be the same committees whose members receive the most campaign contributions from the food and pharmaceutical industries. This may require public campaign financing to be genuinely addressable.
7. Reclassification of Substantial Equivalence: The legal doctrine that GMO foods require no safety testing because they are ‘substantially equivalent’ to natural foods was established by regulatory fiat under industry influence, not by congressional legislation or scientific consensus. It should be revisited through a process that excludes industry-funded science and includes independent international scientific review.

A Note on This Moment

The executive order of February 18, 2026, invoked national security to protect the glyphosate supply. This framing deserves examination. National security is the most powerful justification available to the executive branch — it triggers authorities, overrides normal regulatory processes, and in this case provides partial liability immunity to producers. Designating a probable human carcinogen as a national security asset is not a food safety decision. It is a legal and political maneuver that uses the authority of national defense to insulate a corporate product from accountability.

The MAHA — Make America Healthy Again — movement that RFK Jr. championed as a basis for joining the Trump ticket in 2024 was built substantially on public concern about exactly the chemicals documented in this paper and its companion. The voters who supported that movement were told that an administration committed to MAHA would take on the chemical and food industry interests that were making Americans sick. Within weeks of taking office, the administration invoked the Defense Production Act to protect the most criticized chemical in that movement’s platform. The Environmental Working Group described it as a ‘big middle finger to every MAHA mom.’ That assessment is difficult to dispute on the evidence.

The lesson is not that any particular politician is uniquely culpable. The lesson — which this paper documents from Reagan through Trump, across both parties and six decades — is that the system of capture is more durable than any individual administration’s promises. The corporations have built a system that outlasts elections, political movements, and individual actors. Changing it requires understanding it clearly — which is what this paper attempts to do.

The Conclusion: The system will continue to produce the same outcomes as long as the architecture that generates those outcomes remains intact. Elections change the faces. Structural reform changes the system. The American public has been offered faces. It needs structural reform.

APPENDIX: HOW FAR BACK DOES IT GO — THE DEEP HISTORY OF MANUFACTURED POISON

This appendix asks the question that the preceding chapters imply but leave unasked: Is the pattern documented in Reagan’s FDA, in Nixon’s USDA, in Trump’s executive order — the pattern of corporate capture, manufactured doubt, and revolving-door corruption — a modern phenomenon? Or does it go deeper? And if it goes deeper, what does that tell us about whether it is accidental, structural, or something more deliberate?

The answer, when you look at the documented record, is that it goes back at least a century — and that the same methods, deployed by the same types of actors, for the same financial reasons, have been used to protect at least five major mass poisonings of the American public before glyphosate. The mechanism is always the same. Only the poison changes.

The honest version of this history must also grapple with a distinction that matters enormously to the credibility of this document: the difference between what is documented and what is theorized. What follows is the documented history. Where the evidence is solid, this chapter says so. Where popular narratives overreach the evidence, this chapter says that too — because the documented reality is already damning enough. We do not need to reach for conspiracy to explain what structural incentive and institutional failure explain completely.

1921–1986: Leaded Gasoline — The Ur-Story of Corporate Poison and Manufactured Science

Every element of the corporate capture playbook documented in this paper — the manufactured science, the co-opted regulator, the silenced independent researcher, the revolving door, the claim that the product is safe until proven otherwise — was fully operational by 1924. The poison was lead. The corporations were General Motors, Standard Oil of New Jersey (later ExxonMobil), and DuPont. The product was tetraethyl lead (TEL), added to gasoline to prevent engine knock. The American public was exposed to it for sixty-five years. And the people who knew it was dangerous knew from the very beginning.

In December 1921, Thomas Midgley Jr. — an engineer working for General Motors — discovered that TEL reduced engine knock. The compound had been known since 1854. It had never been used commercially because of, in the words of contemporary scientists, “its known deadliness.” Midgley knew this. He developed lead poisoning himself within two years of beginning his research and was forced to take a leave of absence to recover in Miami. He wrote to colleagues about his lung damage. He knew. GM, Standard Oil, and DuPont knew. Pierre du Pont wrote to his brother Irenée — president of DuPont, which held 38% of GM stock — specifically noting TEL’s “known toxicity” while urging production to continue because of the “potentially large and profitable market.” The toxicity was not discovered later. It was a known condition of launch.

In 1922, the U.S. Surgeon General wrote to Pierre du Pont directly asking about potential health hazards from lead exhaust exposure. The reply, from Midgley, was that there was no experimental data but that GM and DuPont were confident “the average street will probably be so free from lead that it will be impossible to detect it.” Midgley wrote this while personally recovering from lead poisoning. The same year, the League of Nations banned leaded paint in most countries because of documented toxicity in children. TEL entered the market anyway in 1923. By 1924, five workers had died and dozens more were brain-damaged at Standard Oil’s New Jersey refinery in what newspapers called the “loony gas” disaster. The plant was briefly closed. Then the federal government intervened — and production restarted in 1926.

The mechanism by which the lead industry controlled the science for fifty years is one of the most documented stories in the history of regulatory capture. General Motors and DuPont hired Dr. Robert Kehoe of the University of Cincinnati to serve as the industry’s chief medical consultant. Kehoe spent the next four decades producing and controlling research on lead safety — research funded by the Ethyl Corporation, the joint venture of GM and Standard Oil created specifically to manufacture and market TEL. Kehoe’s central contribution was not science. It was a rule. The “Kehoe Rule” — named by historians for its author — held that in the absence of conclusive proof of harm, a product this economically beneficial should not be restricted. In other words: the burden of proof was on those claiming harm, not on those profiting from the product. This was not a neutral scientific principle. It was a doctrine engineered specifically to block regulation. Kehoe also created the concept that observed lead levels in people were “normal” — meaning simply that they were typical — and therefore harmless.

The scientist who broke Kehoe’s stranglehold was Clair Patterson, a Caltech geochemist who had accidentally discovered ubiquitous lead contamination while trying to measure the age of the Earth. Patterson found that modern human bones contained 700 to 1,200 times more lead than the bones of pre-industrial people. He documented that lead levels in the atmosphere had risen by over 1,000 times since the introduction of TEL. His 1965 paper, “Contaminated and Natural Lead Environments of Man,” directly challenged the Kehoe paradigm: the fact that elevated lead levels were common, Patterson argued, said nothing about whether they were safe. What was “normal” was catastrophically poisoned.

The industry responded by trying to destroy him. The Ethyl Corporation first tried to hire Patterson. When he refused, contracts with the California Petroleum Institute and the U.S. Public Health Service were not renewed. The industry allegedly used its influence over Caltech board members to pressure his department chair to fire him. In 1971, Patterson was excluded from a National Research Council panel on atmospheric lead contamination — despite being, by then, the foremost expert on the subject in the world. He was replaced on the panel by industry-aligned researchers. Kehoe called him obsessive and eccentric. The government agency supposed to assess the science depended on the industry for its data.

Patterson won eventually. Leaded gasoline was phased out starting in 1976 and completely banned in 1986. Within a decade of the ban, blood lead levels in Americans dropped by up to 80%. The lead had always been poisoning people. The science had always been there. What took sixty-five years was breaking the institutional grip of the corporations and their hired scientists on the agencies that were supposed to protect the public. Every tactic used against Patterson — contract cancellation, panel exclusion, character attacks, co-opting of government agencies, manufactured doubt — appears, identically, in the Monsanto/glyphosate story that this document’s main chapters describe. The playbook did not change. It was simply transferred.

NOTE ON WHAT WAS KNOWN AND WHEN: The GM archives on early TEL development were described by a GM Institute archivist as having been “sanitized.” The Midgley lab diaries from 1917–1926 have never been released publicly. What is documented — from the Pierre du Pont letter, from Midgley’s own correspondence, from the Surgeon General’s inquiry — is sufficient to establish that toxicity was known before commercial launch. Whether internal documents would establish more deliberate suppression is a question that cannot currently be answered, because those documents have never been released.

1953–1998: Tobacco — The Industry That Wrote the Playbook Everyone Else Now Uses

If the lead industry built the playbook, the tobacco industry perfected it, codified it, and inadvertently made it available to every industry that followed. The internal documents of the tobacco industry — unsealed through litigation in the 1990s — are the most detailed record in existence of how a corporation deliberately manufactures scientific uncertainty to delay accountability while continuing to profit from a product known to be killing its customers.

In December 1953, the presidents of the four largest U.S. tobacco companies met at the Plaza Hotel in New York City with John Hill, founder of the PR firm Hill and Knowlton. Epidemiologists Richard Doll and Austin Bradford Hill had just established a causal link between smoking and lung cancer, and Reader’s Digest had run a mainstream article titled “Cancer by the Carton.” The tobacco executives faced a crisis of public confidence. Their response was not to stop selling cigarettes. It was to construct, with Hill, an industrial-scale campaign of manufactured uncertainty. By January 1954, “A Frank Statement” — an advertisement simultaneously placed in 448 American newspapers, reaching 43 million people — declared that the science was contested, that the tobacco companies cared deeply about public health, and that they were funding independent research to find the truth. None of that was accurate.

A 1969 internal memorandum from Brown and Williamson — a subsidiary of British American Tobacco — made the strategy explicit. It stated that their goal was to manufacture doubt, because doubt was “the best means of competing with the body of fact that exists in the mind of the general public.” It also described doubt as “the means of establishing a controversy.” The tobacco companies funded their own researchers, created front groups that appeared independent, used affiliated academics to publish in peer-reviewed journals, and attacked the credibility of every scientist who found against them. They knew their product caused cancer from internal research conducted as early as the 1950s. They suppressed those findings, publicly denied them, and sold cigarettes for four more decades while the science accumulated and hundreds of thousands of people died annually from a disease those companies understood they were causing.

The tobacco playbook is now the universal template for every industry that has faced scientific evidence of harm. Science historians Naomi Oreskes and Erik Conway documented in Merchants of Doubt that the same PR firms, the same individual operatives, and the same organizational strategies used to defend tobacco were subsequently deployed to manufacture doubt about acid rain, about the ozone-destroying effects of CFCs, about secondhand smoke, and about climate change. The same people. The same firms. The same strategy. The application to food industry science — to saturated fat, to glyphosate, to food additives — follows the identical template. What the tobacco industry created was not just a defense for one product. It was an institution: a mercenary doubt industry available for hire by any corporation facing inconvenient science.

1910: The Rockefeller Question — What Is Documented and What Is Not

The name Rockefeller appears in many accounts of corporate capture of American health, and the question of how much of that story is documented versus theorized matters for this document’s credibility. The answer is: the documented core is real, consequential, and requires no embellishment. The popular embellishments are where the story tends to overreach.

What is documented: John D. Rockefeller controlled approximately 90% of U.S. oil refineries through Standard Oil at the turn of the 20th century. At the same time, organic chemists were discovering that petrochemicals could be used to synthesize pharmaceuticals — compounds that, unlike plant-based or mineral remedies, could be patented, owned, and sold for profit. Rockefeller saw a convergence of opportunity. He founded the Rockefeller Institute for Medical Research in 1901. He donated between $500 million and $1 billion — a sum of enormous consequence in the early 20th century — to medical schools and hospitals, with the condition, in multiple documented cases, that recipients conform to a pharmaceutical-based, allopathic model of medical education. He and Andrew Carnegie jointly funded the publication of the Flexner Report in 1910, authored by Abraham Flexner under the aegis of the Carnegie Foundation. The Flexner Report found that the majority of American medical schools — many of which were teaching homeopathy, herbal medicine, osteopathy, and other modalities — were inadequate. Following its publication and the Rockefeller/Carnegie funding conditions, nearly half of all U.S. medical schools merged or closed. All but two Black medical schools closed. Universities largely reverted to male-only admissions. Alternative medical training was largely eliminated from mainstream education.

The result — a medical system oriented almost entirely toward pharmaceutical intervention, with minimal training in nutrition, prevention, or non-patentable remedies — served Rockefeller’s petrochemical business interests. Whether this outcome was the primary motive or a fortunate byproduct of genuine medical reform is the question that honest historians debate. What is not debated is that the outcome served those interests, that the funding conditions shaped medical education toward pharmaceutical approaches, and that both Rockefeller’s financial interests and the new medical education model shared a common antagonism toward therapies that could not be patented and profited from.

What is not documented, or is substantially overstated in popular accounts: There is no documentary evidence that Rockefeller personally dictated the contents of the Flexner Report. There is no documented evidence that he ordered practitioners of alternative medicine arrested — though some electrotherapy practitioners did face legal action in this period, the chain of causation is not established. The popular narrative that Rockefeller was running a conscious, top-down conspiracy to suppress natural medicine in order to sell drugs rests on inference, not documentation. The documented story — that funding conditions, institutional incentives, and convergent financial interests shaped medical education in directions that served petrochemical pharmaceutical industry profits — is both well-evidenced and deeply troubling. It does not require deliberate conspiracy to be a profound structural corruption of public health. Structural capture is not less serious because it is not explicitly conspiratorial.

THE CONSEQUENCE: A medical system built in this period, shaped by these funding conditions, produced doctors trained to reach for pharmaceutical solutions and largely ignorant of nutrition, environmental toxicology, and prevention. That system is the one that for seventy years told Americans their saturated fat — not the chemicals in their food — was killing them. Whether that was Rockefeller’s plan or his inheritance is a question history cannot definitively answer. That it was his legacy is not in question.

The Pattern: One Poison Ends, the Next One Begins

When you place the documented histories in sequence, a pattern emerges that is difficult to explain as a series of coincidences. Leaded gasoline enters the market in 1923, defended by bought science and a corrupted regulatory process, and poisons the American population for sixty-five years. DDT is introduced in the 1940s, hailed as a miracle compound, defended for decades against independent science, and finally banned in 1972 after Rachel Carson’s Silent Spring forces public reckoning. The tobacco industry’s internal documents show that from 1953 onward, the cancer link was known and suppressed; lawsuits and legislation finally force accountability beginning in the 1990s. Trans fats are introduced as a healthy alternative to butter beginning in the 1950s, defended by industry-funded nutrition science for fifty years, and finally banned in 2018. PFAS compounds are introduced in the 1940s; their persistence and toxicity become clear by the 1990s; they remain almost entirely unregulated into the 2020s. Glyphosate is introduced commercially in 1974; the IARC classifies it as a probable carcinogen in 2015; Bayer settles over 120,000 lawsuits for nearly $11 billion while the U.S. government designates it a national security asset in 2026.

In each case: the product is introduced before safety is established. Independent science raises alarms. Industry funds counter-science and manufactures doubt. Independent scientists face career destruction. Regulators defer to industry data. Decades pass. The harm becomes undeniable. The product is restricted or banned. A new product has already entered the pipeline. The cycle begins again.

The question of whether this cycle is intentional or structural is the most important question in this entire document — and the honest answer is: both, and the distinction matters less than people imagine.

In some cases — the Brown and Williamson memo, the Pierre du Pont letter, the Kehoe Rule — the intent to suppress is explicitly documented. Specific individuals made specific decisions to conceal known harms, knowing that concealment would result in deaths, because the profits outweighed — to those individuals — the human cost. That is not theory. It is documented in their own words.

In other cases — the Flexner Report, the dietary guideline capture documented in the companion paper, the revolving door — the mechanism is structural rather than conspiratorial. No single person needed to plan the outcome. The outcome followed inevitably from a system in which: the people who profit from industrial chemicals fund the science that evaluates those chemicals; the people who regulate those chemicals come from, and return to, the industry being regulated; and the political system that could reform the regulatory process receives its funding from the corporations whose profitability depends on the regulatory status quo.

The structural explanation does not require a secret meeting, a shadowy cabal, or a generational conspiracy passed between dynasties. It only requires a system in which money flows toward those who produce profitable products and away from those who challenge them — and in which the institutions supposed to protect the public from those products are built, funded, and staffed by the people who profit from them. Given those conditions, the cycle of poison, denial, delay, and next poison requires no conspirators. It runs on autopilot. It has been running on autopilot for at least a century. And it will continue to run on autopilot until the structure that generates it is changed.

Who Makes the Call, and Where Does the Money Go

The practical question — who specifically makes the decisions that perpetuate this cycle — has a cleaner answer than conspiracy theories typically provide, and a more disturbing one.

The decisions are made by people doing their jobs. The corporate lawyer who suppresses the internal study documenting harm is doing their job. The lobbyist who kills the regulation is doing their job. The scientist at the industry-funded institute who produces the favorable finding is doing research under conditions designed to produce that finding. The FDA reviewer who approves the product based on the manufacturer’s own safety data is following the process as it was designed. The senator who kills the reform bill after receiving the industry’s campaign contributions is, by the legal standards of the system they operate within, doing nothing wrong. No single person needs to say: I am going to poison the public for profit. They only need to say: I am doing my job.

The money flows in a circuit. Industrial profits fund research that supports industrial products. That research funds journals and academic institutions. Those institutions train the regulators and the scientists who assess the products. Campaign contributions from industrial profits fund the politicians who appoint those regulators and pass the laws under which those scientists operate. Consulting revenue from industrial profits funds the think tanks and PR firms that shape public opinion about the safety of those products. And the profits continue, sustaining the circuit, year after year, poison after poison.

The people at the top of this circuit — the C-suite executives, the major shareholders — do, sometimes, make knowing decisions that they understand will perpetuate harm. The Brown and Williamson memo proves this for tobacco. The Pierre du Pont letter proves this for lead. The Monsanto internal documents produced in the Roundup litigation prove this for glyphosate: internal researchers who reached findings the company did not like were asked to revise them; regulatory filings contained data selectively chosen to support approval; scientists who published against the product faced company-coordinated campaigns to discredit them. These are not allegations. They are the contents of documents produced in discovery, admitted in litigation, and now part of the public record.

But the system does not depend on such knowing decisions at every level. It only needs them at enough levels to keep the circuit intact. The underpaid FDA reviewer who has never been offered a job by the industry is still operating within a process that the industry shaped. The academic nutritionist who genuinely believes the science they were trained on is still teaching a curriculum whose foundations were established through funding conditions set decades ago. The structural capture is so complete that it does not require active, knowing participation at every point. The bias is baked in. The system produces the outcome without needing a conspirator at every node.

THIS IS THE HONEST ANSWER TO THE CONSPIRACY QUESTION: Some of the harm is the result of deliberate, documented choices by identifiable individuals to suppress known dangers for profit. Some of it is the result of a structural system that produces those outcomes without requiring deliberate choices. Both are happening simultaneously. Both are real. The structural explanation is not a lesser claim than the conspiratorial one — it is a more alarming one, because it is harder to fix. You can prosecute a conspirator. You cannot prosecute a system.

Sources

Wikipedia: Tetraethyllead — History, toxicity, regulatory timeline, and role of Midgley, Kettering, DuPont, Standard Oil, and the Ethyl Gasoline Corporation.

The Nation / Jamie Lincoln Kitman (2000): “The Secret History of Lead.” Detailed reconstruction of the TEL commercialization, the GM archive sanitization, the public health suppression, and the Kehoe Rule. Primary sourcing throughout.

Wikipedia: Clair Patterson — Documented account of career destruction by Ethyl Corporation, exclusion from NRC panel in 1971, and eventual vindication. National Academies biographical memoir also cited.

Wikipedia: Robert A. Kehoe — Documented account of Kehoe’s role as Ethyl Corporation’s chief medical consultant, the Kehoe Rule, and his commission by DuPont to produce favorable findings on carcinogenic compounds.

Wikipedia / Tobacco Industry Playbook — 1969 Brown and Williamson internal memorandum; the 1953 Plaza Hotel meeting; the Frank Statement of 1954. Documented in Naomi Oreskes and Erik Conway, Merchants of Doubt (2010).

PMC12318542: Swenson et al. (2025) — “Rockefeller, the Flexner Report, and the American Medical Association.” Peer-reviewed historical analysis drawing on previously unpublished Rockefeller Foundation internal reports by Frederick T. Gates. Most thorough primary-source account of the Flexner/Rockefeller relationship.

Wikipedia: Flexner Report — Documented consequences including closure of Black medical schools, AMA centralization, and alternative medicine elimination. Rockefeller/Carnegie funding conditions documented.

Organometallics, Vol. 22 (2003): “The Rise and Fall of Tetraethyllead.” Peer-reviewed chemical history documenting the Pierre du Pont letter on TEL toxicity and the DuPont/GM institutional relationship during commercialization.

David Michaels: Doubt Is Their Product (2008). Definitive account of the mercenary doubt industry that spawned from the tobacco playbook and now operates across all industries facing inconvenient science.

SOURCES AND CITATIONS

The Revolving Door — Documented Personnel Movements

Alliance for Human Research Protection (AHRP, 2017): ‘How Monsanto Rigged the System: Through Politics and Propaganda.’ Comprehensive documentation of Monsanto-government personnel movements from Reagan through Obama. ahrp.org

U.S. Right to Know (USRTK): ‘The Agrichemical Companies Have a Potent Political Machine.’ Documents Michael Taylor, Tom Vilsack, Clarence Thomas, Mitt Romney, Hillary Clinton and others. usrtk.org

Wisner Baum law firm documented case archive (2017): ‘Monsanto Government Influence Has Fueled Unrivaled Corporate Power.’ Documents Margaret Miller, Michael Friedman, Jess Rowland, Linda Fisher, Ruckelshaus. wisnerbaum.com

Oyez Project, Chicago-Kent College of Law: Biography of Justice Clarence Thomas — confirms Monsanto pesticide/agriculture division employment 1977–1979.

Michael Taylor revolving door career: FDA 1970s → King & Spalding (Monsanto counsel) 1981–91 → FDA 1991–94 → USDA 1994–96 → Monsanto VP 1996–2009 → FDA Senior Advisor 2009 → FDA Deputy Commissioner 2010. Documented across: USRTK, AHRP, New York Times (Michael Moss, 2009), Little Sis database.

Metabunk.org partial debunking thread (2014): Confirms Taylor, Thomas, and core revolving door figures while noting some details in circulating infographics are imprecise. Provides sourced corrections. Used to verify accuracy of specific claims in this paper.

The Monsanto Protection Act

Food First (archive.foodfirst.org): ‘The Monsanto Protection Act of Betrayal.’ Documents Section 735 of H.R. 933, Senator Roy Blunt’s authorship, Obama’s signature on March 26, 2013, and the 250,000-person petition.

U.S. Right to Know: Detailed analysis of Section 735 language and its court-stripping function.

White House ‘Has Monsanto’s Back’ — Internal Documents

U.S. Right to Know (March 2021): ‘White House Has Monsanto’s Back on Pesticides, Newly Revealed Document Says.’ Documents Hakluyt intelligence report to Monsanto (July 2018), quoting White House domestic policy adviser and EPA/USDA officials confirming protection of glyphosate from additional regulation. usrtk.org

Pilliod v. Monsanto litigation (California Superior Court): Court filings referencing Hakluyt report and Jess Rowland ‘medal’ allegation. Filed as part of Roundup cancer litigation discovery.

Trump Glyphosate Executive Order — February 18, 2026

White House Fact Sheet (February 18, 2026): ‘President Donald J. Trump Ensures an Adequate Supply of Elemental Phosphorus and Glyphosate-Based Herbicides for National Security.’ whitehouse.gov

White House Presidential Action (February 18, 2026): Full text of executive order invoking Defense Production Act. whitehouse.gov/presidential-actions

CNBC (February 18, 2026): ‘Trump order pushes glyphosate production; Roundup chemical hated by MAHA.’ Covers Kennedy’s position change and Monsanto/Bayer response.

Environmental Working Group (February 18, 2026): ‘EWG: Trump’s glyphosate executive order a big middle finger to every MAHA mom.’ EWG President Ken Cook’s statement. ewg.org

The Focal Points (February 18, 2026): ‘Breaking: Trump Invokes Defense Production Act to Protect Glyphosate.’ Analysis of Section 707 compliance immunity implications for cancer litigation.

Bloomberg (February 18, 2026): ‘Trump Invokes Defense Law on Phosphorus, Herbicide Supplies.’

Bayer glyphosate litigation settlement: $11 billion to settle 120,000+ lawsuits, reported across Reuters, AP, and financial press, 2020–2023.

Pharmaceutical and Agribusiness Campaign Finance and Lobbying

Wouters OJ, PMC7054854 / JAMA Internal Medicine (2020): ‘Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999–2018.’ $4.7 billion in lobbying; $414 million in campaign contributions; 39 of 40 top recipients on health committees.

OpenSecrets (2025): ‘Federal Lobbying Set New Record in 2024.’ Pharmaceutical industry spent $384.5 million in 2024; $6.1 billion total since 1999. opensecrets.org

OpenSecrets (2023): ‘Despite Record Spending, Pharma Lost Its Biggest Bet in 2022.’ $372 million in 2022; 1,834 registered lobbyists; more than 3 per member of Congress; over half are revolving-door hires. opensecrets.org

Union of Concerned Scientists / The Hill (May 2024): ‘Farm Bill Lobbying Exceeds $500 Million.’ Agribusiness and food industry spent $523 million on Farm Bill lobbying 2019–2023 — four times public interest sector spending. farmpolicynews.illinois.edu

Statista (2024): Leading lobbying industries U.S. — pharmaceuticals/health products top spender at $293.7 million; pharmaceutical industry dominant since 1950.

EPA Glyphosate Assessment and Regulatory Capture

Toxicology Reports (2021): ‘How did the U.S. EPA and IARC reach diametrically opposed conclusions on the genotoxicity of glyphosate-based herbicides?’ Documented reliance on industry vs. independent studies.

IARC Monographs Vol. 112 (2015): Classification of glyphosate as Group 2A probable human carcinogen.

Investigate Midwest (July 2021): ‘The Biden Administration Has Defended Some of Former President Trump’s Pesticide Decisions.’ Documents Biden EPA use of Trump-era methodology for malathion, defense of dicamba registration. investigatemidwest.org

Center for Food Safety: Statement on Trump administration pulling new GMO biotech rules, 2017. centerforfoodsafety.org

Supreme Court and Seed Patents

J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., 534 U.S. 124 (2001). Justice Thomas majority opinion establishing plant utility patent validity. Legal text at supreme.justia.com

Oyez Project: Justice Thomas biography, Monsanto employment confirmation.

Philip Howard, Michigan State University: ‘Seed Industry Structure 1996–2018.’ Documents consolidation from hundreds of seed companies to three controlling 60% of global market.

This paper may be reproduced and shared freely for non-commercial public education purposes.

Read alongside its companion paper: POISONED BY DESIGN